SAB Biotherapeutics (SABS) Long-Term Debt Issuances (2020 - 2021)

SAB Biotherapeutics (SABS) reported Long-Term Debt Issuances of $150000.0 for Q1 2021, little changed quarter-over-quarter from $150000.0 in Q4 2020.

SAB Biotherapeutics (SABS) Long-Term Debt Issuances (2020 - 2021) Analysis & Trends

SAB Biotherapeutics has reported Long-Term Debt Issuances for 2 years, with the latest figure at $150000.0 in Q1 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Issuances (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	2.73 Mn
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	-
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	SAB Biotherapeutics	214.77 Mn	214.77 Mn	-	-

Download Data